Replies to post #204890 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

Riddle :

Is Missling holding to his word of designed to fail and if the data supports failure, the study would be over not extended. He's thrifty!

That is my question also. None of us has posted that he is just confused or that there are results that are being WASHED for new PR claims, Like BIIB.

This is at least an interesting consideration. PM trials are bound to have serious questions about...NOW WHAT? In the dark days when everything failed this was not a problem when they just redefined success as w/current SOC.

An interesting question. Are we in the gray area between obvious failure and we don't know b/c we don't know what success really looks like? I am sure that at some point it will be unbearable and either a better definition for pass/fail will be written or it is obvious the patients have not improved yet. If a trial is continued b/c we think it is good, then what?

Since no one has ever demonstrated that CNS cellular Homeostasis has been restored we really are uncertain on how to define success. (see the famous guy who said the light has been turned on in a dark room). So I guess the old log books and ADL metrics apply. Cannot wait for some good solid ERP data.

[imho]

Is Missling holding to his word of designed to fail and if the data supports failure, the study would be over not extended.

This often quoted statement needs to be scrutinized, IMO, given Misslings weak grasp of the English language. I doubt the trials are designed to fail. What he probably means is that the design is focused on gathering information that identifies a common failure "thread". Use of this information will be used to minimize failure in future trials. It is a subtle point.

IMHO